Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 9 November 2017

LIDDS initiates research collaboration with the Karolinska Institute

LIDDS AB    

Published: 08:00 CET 09-11-2017 /GlobeNewswire /Source: LIDDS AB / : LIDDS /ISIN: SE0001958612

LIDDS initiates research collaboration with the Karolinska Institute

LIDDS has entered a research collaboration with the Department of Laboratory Medicine at Karolinska Institute, Sweden. The collaboration regards fundamental preclinical studies on formulations based on the NanoZolid® technology, as well as access to risk laboratories for formulation development.

 

LIDDS broadens its R&D activities to develop novel NanoZolid® formulations for local tumor therapy by establishing a collaboration with Professor Mustapha Hassan and Dr. Ying Zhau at the Department of Laboratory Medicine (LABMED) at Karolinska Institute in Huddinge.

 

-    LIDDS appreciate very much the collaboration with KI, and I am confident that the ongoing collaborative research will be fruitful and supportive to develop new efficient formulations with the NanoZolid® technology. We are also pleased with the preclinical expertise that we have encountered at the Department Laboratory Medicine at Novum, states CEO of LIDDS Monica Wallter.

The collaboration includes fundamental preclinical studies and gives access to risk laboratories for formulation development with hazardous substances. Within the frame of the collaboration, novel NanoZolid® formulations will be investigated prior to entering the clinical phase.

 

For more information, please contact:

Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: monica.wallter@liddspharma.com                     

 

LIDDS is required to disclose the information in this press release under the European Union's Market Abuse Regulation and the Securities Market Act. The information was submitted through the agency of the aforementioned contact person for publication on 9 November 2017 at 08.00 CET.

                 

About Lidds

LIDDS AB (publ) develops effective medications for cancer and other diseases with the patented NanoZolid® technology. NanoZolid® releases the medication locally and efficiently, which means significantly fewer side effects and treatments compared with systemic treatment. NanoZolid® technology allows for the controlled, long-term and adjusted release of the medication for up to six months. NanoZolid® can be combined with both large and small pharmaceutical molecules, such as antibodies. The company's most advance project is the prostate cancer product Liproca® Depot, which contains 2-hydroxyflutamide, which confirms that the technology has a documented clinical effect. The prostate cancer project is currently in Phase IIb. Industrial-scale production is taking place in collaboration with Recipharm. LIDDS has active development projects where NanoZolid®is combined with antiandrogens, cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq, First North. Redeye AB is a certified adviser to LIDDS AB. For more information, go to www.liddspharma.com.



The News in PDF



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: LIDDS AB, Kullagatan 8, Helsingborg SE-252 20, Sweden
If you would like to unsubscribe and stop receiving these e-mails click here.